Optimistic News Make Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) Explode
Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH)’s stock is rarely traded much and usually stays below $50 thousand in dollar volume. The past 6 sessions didn’t even manage to go beyond $10 thousand in trade value, but yesterday’s press release livened EAPH a bit.
Even though EAPH come out with optimistic PR from time to time, the stock simply can’t attract that much investor attention. The last time the company stock was promoted was back in the beginning of June and led to a catastrophic outcome.
Since then the stock managed to recover some of its value and climbed above $0.010 per share in the beginning of September, but started to slide down and we saw the number of traded shares drop substantially.
That was until yesterday when EAPH announced that the company has purchased an initial 10% ownership interest in an experimental cancer drug, called XILIVE, from a private Canadian company.
If you have been following EAPH‘s development you would start to wonder how come they went from treatment of female sexual dysfunction, cellulite and scar and stretch mark treatment to treating cancer.
Nonetheless, there were a lot of people who got excited from the press release and we saw a massive gain of 112% in EAPH‘s price yesterday. The ticker closed at $0.0053 with almost 10 times the average volume, a massive of 51 million shares switching hands, in term generating $255 thousand in dollar volume.
What is more disturbing, however, is the fact that we didn’t find any clues about the so called Xilive drug or its manufacturer, despite the fact that there have already been 2 cases in which the drug has been administered to patients with cancer.
Indeed, EAPH mentioned in the press release (the only place where where we find Xilive on the world wide web) that despite the fact that both patients are in remission, it is still uncertain if this is a result of the treatment.
However, we reckon that many people didn’t take the time to investigate the matter in more detail and jumped on initial impressions, contributing for yesterday’s booming session. This is the exact reason for which we would advise you to do a lot of due diligence and weigh out the risks.
Another company that is trying to lure investors with possibilities for cancer treatment drugs, that would bring great profits is Nuvilex, Inc. (OTCMKTS:NVLX). Their stock’s price movement, however, isn’t one of the greatest as the value of the ticker regularly crashes for long periods of time.
We have been following Pan Global Corp (OTCMKTS:PGLO) for a few days now and they managed to totally obliterate the gain in price they registered in 2 weeks of trading, losing a further 48% in yesterday’s session.
